TABLE 3.
Treatment‐emergent adverse events (AEs) in the overall study population and the ABVD subgroup. In each cohort, AEs are presented by age (< and ≥ 60 years old). *Chi‐square test, Fisher exact P < 0.05
| Systemic treatment 1L | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABVD (N = 221) | Overall total (N = 256) | |||||||||||
| Age < 60 | Age ≥ 60 | Age < 60 | Age ≥ 60 | |||||||||
| N = 221 | N = 190 | N = 31 | N = 256 | N = 214 | N = 42 | |||||||
| N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | |
| Neutropenia (all‐grade) | 104 | 47.1 | 87 | 45.8 | 17 | 54.8 | 125 | 48.8 | 103 | 48.1 | 22 | 52.4 |
| Febrile neutropenia | 15 | 6.8 | 10 | 5.3 | 5 | 16.1* | 28 | 10.9 | 21 | 9.8 | 7 | 16.7* |
| Anemia | 61 | 27.6 | 49 | 25.8 | 12 | 38.7 | 82 | 32.0 | 66 | 30.8 | 16 | 38.1 |
| Infection (bacterial/viral) | 49 | 22.2 | 38 | 20 | 11 | 35.5* | 61 | 23.8 | 47 | 22 | 14 | 33.3* |
| pulmonary toxicity | 22 | 10 | 18 | 9.5 | 4 | 12.9 | 25 | 9.8 | 21 | 9.8 | 4 | 9.5 |
| Cardiovascular complications | 5 | 2.3 | 2 | 1.1 | 3 | 9.7* | 6 | 2.3 | 3 | 1.4 | 3 | 7.1* |
| Neuropathy | 13 | 5.9 | 11 | 5.8 | 2 | 6.5 | 18 | 7.0 | 15 | 7 | 3 | 7.1 |
| Thrombocytopenia | 6 | 2.7 | 5 | 2.6 | 1 | 3.2 | 13 | 5.1 | 12 | 5.6 | 1 | 2.4 |
| Hepatic toxicity | 6 | 2.7 | 5 | 2.6 | 1 | 3.2 | 6 | 2.3 | 5 | 2.3 | 1 | 2.4 |
Notes: Age at initiation of 1L; *Chi‐square test, Fisher exact p < 0.05.